冷冻囊胚移植前延长雌激素(E2)治疗降低活产率
该观察性队列研究纳入1377例自体冷冻复苏囊胚移植周期,按移植前雌激素暴露时长分为≤21天、22-28天、29-35天和36-48天四组。多因素回归显示,E2暴露超过28天与活产率下降相关,超过35天与早期妊娠丢失率升高相关。作者认为移植前E2暴露时长不应超过28天。
要点
- E2暴露29-35天组活产率较≤21天组降低(OR=0.66)。
- E2暴露36-48天组活产率较≤21天组降低(OR=0.49)。
- E2暴露超过35天组早期妊娠丢失率较≤21天组升高(OR=2.37)。
核心结论
- 在人工内膜准备(AEP)方案中,冷冻囊胚移植前延长雌激素暴露会显著降低自体冷冻复苏囊胚移植后的活产率。
- 作者认为,为使患者获得最佳活产机会,冷冻囊胚移植前E2暴露时长不应超过28天。
研究设计与样本
- 观察性队列研究,于2012年7月1日至2015年12月31日在三级大学医院开展。
- 共纳入1377例采用外源性E2行AEP的单囊胚冷冻复苏移植周期。
- 按移植前E2给药时长分为≤21天组(n=330)、22-28天组(n=665)、29-35天组(n=289)和36-48天组(n=93),以≤21天组为参照组。
- 采用单因素和多因素logistic回归模型进行统计分析。
主要发现
- 与参照组相比,29-35天组活产率降低(OR=0.66,95%CI 0.46-0.95,P=0.026)。
- 与参照组相比,36-48天组活产率降低(OR=0.49,95%CI 0.27-0.89,P=0.018)。
- 与参照组相比,E2暴露超过35天组早期妊娠丢失率升高(OR=2.37,95%CI 1.12-5.05,P=0.025)。
- 多因素logistic回归后,29-35天组活产率降低(OR=0.65,95%CI 0.45-0.95,P=0.044)。
- 多因素logistic回归后,36-48天组活产率降低(OR=0.49,95%CI 0.26-0.92,P=0.035)。
临床怎么用
- 作者认为,冷冻囊胚移植前E2暴露时长不应超过28天,以给患者最佳活产机会。
局限性
- 该研究的局限性之一与其观察性设计有关。
- 作者结论中提出E2暴露不应超过28天,该建议基于观察性研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How does the duration of estrogen (E2) treatment prior to frozen-blastocyst transfers affect the live birth rate (LBR)? SUMMARY ANSWER: Prolonged E2 exposure as part of artificial endometrial preparation (AEP) significantly decreases the LBR after autologous frozen-thawed blastocyst transfer. WHAT IS KNOWN ALREADY: One effective method for endometrial preparation prior to frozen embryo transfer is AEP, a sequential regimen with E2 and progesterone, which aims to mimic the endocrine exposure of the endometrium in a normal cycle. Nevertheless, the optimal duration of E2 administration prior to transfer remains unknown. STUDY DESIGN, SIZE, DURATION: An observational cohort study was conducted in a tertiary care university hospital between 01/07/2012 and 31/12/2015. The main inclusion criteria was having a single frozen-thawed blastocyst transfer with an AEP using exogenous E2. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 1377 frozen-thawed blastocyst transfers were assigned to four groups according to the duration of the E2 administration prior to the embryo transfers. These comprised a '≤21 days' group (n = 330), a '22-28 days' group (n = 665), a '29-35 days' group (n = 289) and a '36-48 days' group (n = 93). The '≤21 days' group' was taken as the reference group. The main measured outcome was the LBR following frozen-thawed blastocyst transfers. Statistical analysis was conducted using univariate and multivariate logistic regression models. MAIN RESULTS AND THE ROLE OF CHANCE: LBR significantly decreased when the E2 exposure prior to the frozen-thawed blastocyst transfer exceeded 28 days: OR = 0.66; 95% CI [0.46-0.95]; P = 0.026 and OR = 0.49 [0.27-0.89]; P = 0.018, respectively, for the '29 to 35 days' group and for the '36 to 48 days' group compared to the reference group. Early pregnancy loss rates significantly increased when the E2 exposure lasted more than 35 days prior to the frozen-thawed blastocyst transfer (OR = 2.37 [1.12-5.05]; P = 0.025 vs. the reference group). After multivariate logistic regression, E2 exposure lasting more than 28 days prior to the frozen-thawed blastocyst transfer was associated with a decrease in the LBR, for the '29-35 days' group (OR = 0.65; [0.45-0.95]; P = 0.044) as for the '36-48 days' group (OR = 0.49; [0.26-0.92]; P = 0.035), vs. the reference group. LIMITATIONS, REASONS FOR CAUTION: One limitation is linked to the observational design of this study. WIDER IMPLICATIONS OF THE FINDINGS: In order to give patients the best chance to obtain a live birth after frozen-thawed blastocyst transfer, the length of E2 exposure prior to the frozen-blastocyst transfer should not exceed 28 days. This study provides new insight in regard to endometrial preparation using AEP prior to frozen-blastocyst transfer. STUDY FUNDING/COMPETING INTEREST(S): No funding and no competing interest.
引用
- Bourdon M, Santulli P, Kefelian F, et al. Prolonged estrogen (E2) treatment prior to frozen-blastocyst transfer decreases the live birth rate. Hum Reprod. 2018. PMID: 29529202. doi:10.1093/humrep/dey041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。